DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

PK/PD of Ertapenem In Patients With TB

Information source: University Medical Center Groningen
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: PK of Ertapenem in TB Patients

Intervention: ertapenem (Drug)

Phase: Phase 2

Status: Suspended

Sponsored by: University Medical Center Groningen


Rationale: Treatment of multidrug or extensively drug resistant tuberculosis (MDR/XDR-TB) is a real challenge as failure in response to treatment and serious side-effects are frequently encountered. New, more effective drugs with less side effects are therefore urgently needed to solve this problem. Although several new drugs against TB are in the pipeline, physicians currently have limited treatment options for treatment of complicated MDR/XDR-TB cases. Therefore, drugs developed and labeled for other infectious diseases are evaluated for TB. Objective: The main objective of this prospective clinical trial is to evaluate pharmacokinetics of a standard dose (1000mg) of ertapenem in TB patients. This clinical trial will provide important information on PK of ertapenem in TB patients for future studies. Data can be used for limited sampling strategies for ertapenem based on a pharmacokinetic population model constructed from the full PK curves of the patients. Study design: A prospective pharmacokinetic study. Study population: 12 TB patients. Intervention: Single dose of 1000mg in a 30 minutes intravenous infusion. Main study parameters/endpoints: The pharmacokinetic parameters (Vd, Cl, AUC, etc) of ertapenem are the primary endpoints of the study. The T>MIC and AUC0-24h/Minimal inhibitory concentration (MIC) ratio are most likely the best predictive parameters for efficacy of ertapenem treatment and will be calculated for a range of M tuberculosis isolates.

Clinical Details

Official title: Pharmacokinetics and Pharmacodynamics of Ertapenem in Patients With Tuberculosis

Study design: Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label

Primary outcome: AUC

Secondary outcome: Safety: number of patients with organ dysfunction


Minimum age: 18 Years. Maximum age: 64 Years. Gender(s): Both.


Inclusion Criteria:

- Patients with TB, with Mycobacterium tuberculosis (or M. africanum) by culture

- Adults: from 18 years until 64 years of age

Exclusion Criteria:

- Contra-indications for ertapenem:

- There are few adverse effects of ertapenem. The only absolute contra- indication is a

previous anaphylactic reaction to ertapenem or other β-lactam antibiotic.

- Renal Insufficiency, defined by a eGFR of 30ml/min

- Pregnancy


- Body weight < 40 kg

Locations and Contacts

UMCG - Tuberculosis Center, Groningen, Netherlands
Additional Information

Related publications:

Tremblay LW, Fan F, Blanchard JS. Biochemical and structural characterization of Mycobacterium tuberculosis beta-lactamase with the carbapenems ertapenem and doripenem. Biochemistry. 2010 May 4;49(17):3766-73. doi: 10.1021/bi100232q.

Starting date: February 2013
Last updated: June 17, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017